Replimune Group Inc
(NAS:REPL)
$
12.355
-0.345 (-2.72%)
Market Cap: 844.11 Mil
Enterprise Value: 474.85 Mil
PE Ratio: 0
PB Ratio: 1.98
GF Score: 39/100 
Replimune Group Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020 / 01:00AM GMT
Release Date Price:
$18.27
(+1.61%)
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst
Start?
Philip Astley;Sparke
Replimune Group, Inc. - Chairman, CEO, Secretary & Treasurer
Yes.
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst
Okay. So welcome to the Tuesday afternoon session of the 2020 JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is Replimune, and presenting on behalf of the company is CEO, Philip Astley-Sparke.
Philip Astley;Sparke
Replimune Group, Inc. - Chairman, CEO, Secretary & Treasurer
Thanks, Anupam. Safe harbor. So Replimune. Replimune was founded in 2015 to realize the full potential of oncolytic immunotherapy. We believe that our products become the second cornerstone of immuno-oncology. Our lead asset, RP1, primarily focuses on immuno-responsive
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers